References
- 1. ANGELI P., MERKEL C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008; 48(Suppl 1):S93-103.
- 2. PHAM PT., PHAM PC., RASTOGI A., WILKINSON AH. Review article: current management of renal dysfunction in the cirrhotic patient. Aliment Pharmacol Ther. 2005; 21(8):949-61.
- 3. CÁRDENAS A., GINÈS P. Hepatorenal syndrome. Clin Liver Dis. 2006; 10(2):371-85.
- 4. GINÈS A., ESCORSELL A., GINÈS P., SALÓ J., JIMÉNEZ W., INGLADA L., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993; 105(1):229-36.
- 5. ARROYO V., TERRA C., GINÈS P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007; 46(5):935-46.
- 6. TSOCHATZIS EA., BOSCH J., BURROUGHS AK. Liver cirrhosis. Lancet. 2014; 383(9930):1749-61.
- 7. ARROYO V., GINÈS P., GERBES AL., DUDLEY FJ., GENTILINI P., LAFFI G., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996; 23(1):164-76.
- 8. SALERNO F., GERBES A., GINÈS P., WONG F., ARROYO V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007; 56(9):1310-8.
- 9. CHOLONGITAS E., CALVARUSO V., SENZOLO M., PATCH D., SHAW S., O'BEIRNE J., et al. RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol. 2009; 24(10):1639-47.
- 10. MYERS RP., LEE SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 2000; 6(4 Suppl 1):S44-52.
- 11. BERNARDI M., RUBBOLI A., TREVISANI F., CANCELLIERI C., LIGABUE A., BARALDINI M., et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol. 1991; 12(2):207-16.
- 12. MONCRIEF K., KAUFMAN S. Splenic baroreceptors control splenic afferent nerve activity. Am J Physiol Regul Integr Comp Physiol. 2006; 290(2):R352-6.
- 13. GUARNER C., SORIANO G., TOMAS A., BULBENA O., NOVELLA MT., BALANZO J., et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology. 1993; 18(5):1139-43.
- 14. ANGELI P. Hepatorenal syndrome. In: Vincent J-L 2006 Yearbook of Intensive Care and Emergency Medicine. Ed. Springer- Verlag, Berlin, 2006; p. 661-70.
- 15. FERNÁNDEZ J., NAVASA M., PLANAS R., MONTOLIU S., MONFORT D., SORIANO G., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007; 133(3):818-24.
- 16. DAGHER L., MOORE K. The hepatorenal syndrome. Gut. 2001;4 9(5):729-37.
- 17. NIETSCH HH. Management of portal hypertension. J Clin Gastroenterol. 2005; 39(3):232-6.
- 18. GENZINI T., TORRICELLI FC. Hepatorenal syndrome: an update. Sao Paulo Med J. 2007; 125(1):50-6.
- 19. SUZUKI H., STANLEY AJ. Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome. QJM. 2001; 94(6):293-300.
- 20. KASHANI A., LANDAVERDE C., MEDICI V., ROSSARO L. Fluid retention in cirrhosis: pathophysiology and management. QJM. 2008; 101(2):71-85.
- 21. GINÈS P., TORRE A., TERRA C., GUEVARA M. Review article:pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther. 2004; 20(Suppl 3):57-62; discussion 63-4.
- 22. GINÈS P., CÁRDENAS A., ARROYO V., RODÉS J. Management of cirrhosis and ascites. N Engl J Med. 2004; 350(16):1646-54.
- 23. MARRERO J., MARTINEZ FJ., HYZY R. Advances in critical care hepatology. Am J Respir Crit Care Med. 2003; 168(12):1421-6.
- 24. RUNYON BA., AASLD PRACTICE GUIDELINES COMMITTEE. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49(6):2087-107.
- 25. SOLANKI P., CHAWLA A., GARG R., GUPTA R., JAIN M., SARIN SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003; 18(2):152-6.
- 26. DUNDAR HZ., YILMAZLAR T. Management of hepatorenal syndrome. World J Nephrol. 2015; 4(2): 277-286.
- 27. MARTÍN-LLAHÍ M., PÉPIN MN., GUEVARA M., DIAZ F., TORRE A., MONESCILLO A. et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008; 134(5):1352-9.
- 28. KALAMBOKIS G., ECONOMOU M., FOTOPOULOS A., AL BOKHARHII J., PAPPAS C., KATSARAKI A., et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005; 100(4):879-85.
- 29. DAVENPORT A., AHMAD J., AL-KHAFAJI A., KELLUM JA., GENYK YS., NADIM MK. Medical management of hepatorenal syndrome. Nephrol Dial Transplant. 2012; 27(1):34-41.
- 30. TURBAN S., THULUYATH PJ., ATTA MG. Hepatorenal syndrome. World J Gastroenterol. 2007; 13(30):4046-55.
- 31. LOW G., ALEXANDER GJ., LOMAS DJ. Hepatorenal syndrome: aetiology, diagnosis, and treatment. Gastroenterol Res Pract. 2015; 2015:207012.
- 32. VOLK ML., MARRERO JA. Advances in critical care hepatology. Minerva Anestesiol. 2006; 72(5):269-81.
- 33. KAPTANOGLU L., BLEI AT. Current status of liver support systems. Clin Liver Dis. 2000; 4(3):711-29, 34. BRENSING KA., TEXTOR J., PERZ J., SCHIEDERMAIER P., RAAB P., STRUNK H., et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000; 47(2):288-95.
- 35. SEN S., MOOKERJEE RP., DAVIES NA., WILLIAMS R., JALAN R. Review article: the molecular adsorbents recirculating system (MARS) in liver failure. Aliment Pharmacol Ther. 2002; 16(Suppl 5):32-8.
- 36. WIKLUND RA. Preoperative preparation of patients with advanced liver disease. Crit Care Med. 2004; 32(4 Suppl):S106-15.
- 37. SOLIS-HERRUZO JA., DURAN A., FAVELA V., CASTELLANO G., MADRID JL., MUÑOZ-YAGÜE MT., et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol. 1987; 5(2):167-73.
- 38. TANDON P., BAIN VG., TSUYUKI RT., KLARENBACH S. Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials. Aliment Pharmacol Ther. 2007; 25(9):1017-28.
- 39. ALESSANDRIA C., OZDOGAN O., GUEVARA M., RESTUCCIA T., JIMÉNEZ W., ARROYO V., et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005; 41(6):1282-9.
- 40. SCHEPKE M., APPENRODT B., HELLER J., ZIELINSKI J., SAUERBRUCH T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int. 2006; 26(7):834-9.